Biotech Values

[DewDiligence]

PLX—Yet another company enters NASH arena:

http://finance.yahoo.com/news/protalix-biotherapeutics-explore-non-alcoholic-120000696.html

CARMIEL, Israel, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. announced today pre-clinical data for PRX-106 in Non-alcoholic Steatohepatits (NASH)… PRX-106 is the Company's orally administered, plant cell-expressed recombinant anti-TNF fusion protein that successfully concluded Phase I clinical trial.

In preclinical studies, PRX-106 alleviated immune-mediated hepatitis and reduced interferon gamma levels in a concanavalin A (ConA) inflammatory mouse model. Furthermore, the drug was shown to alleviate liver damage and reducing liver necrosis and reduction of liver enzymes, ALT and AST, thus leading to an improvement in liver biopsies. In a high fat diet model (NASH) PRX 106 demonstrated a reduction of liver enzymes, ALT and AST, reduction of serum triglycerides, along with a trend for reduction of liver fat.

Beware of that waffle word, trend.